Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
As of close of business last night, NewAmsterdam Pharma Company NV’s stock clocked out at $38.12, up 4.37% from its previous closing price of $36.53. In other words, the price has increased by $4.37 from its previous closing price. On the day, 1.67 million shares were traded. NAMS stock price reached its highest trading level at $40.74 during the session, while it also had its lowest trading level at $35.422.
Ratios:
To gain a deeper understanding of NAMS’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 21.08 and its Current Ratio is at 21.08. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
On August 25, 2025, Wells Fargo started tracking the stock assigning a Overweight rating and target price of $45.
On July 17, 2025, Goldman started tracking the stock assigning a Neutral rating and target price of $27.Goldman initiated its Neutral rating on July 17, 2025, with a $27 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Sep 15 ’25 when Topper James N bought 660 shares for $23.70 per share. The transaction valued at 15,639 led to the insider holds 3,028,524 shares of the business.
Kooij Louise Frederika sold 150,000 shares of NAMS for $3,874,017 on Sep 09 ’25. The Chief Accounting Officer now owns 15,000 shares after completing the transaction at $25.83 per share. On Sep 08 ’25, another insider, Topper James N, who serves as the Director of the company, bought 1,260 shares for $24.99 each. As a result, the insider paid 31,487 and bolstered with 3,027,864 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NAMS now has a Market Capitalization of 4323024384 and an Enterprise Value of 3375483648. For the stock, the TTM Price-to-Sale (P/S) ratio is 67.08 while its Price-to-Book (P/B) ratio in mrq is 5.51. Its current Enterprise Value per Revenue stands at 52.737 whereas that against EBITDA is -19.555.
Stock Price History:
The Beta on a monthly basis for NAMS is 0.07, which has changed by 0.61351585 over the last 52 weeks, in comparison to a change of 0.13367426 over the same period for the S&P500. Over the past 52 weeks, NAMS has reached a high of $41.47, while it has fallen to a 52-week low of $14.06. The 50-Day Moving Average of the stock is 23.31%, while the 200-Day Moving Average is calculated to be 64.84%.
Shares Statistics:
It appears that NAMS traded 1.05M shares on average per day over the past three months and 781540 shares per day over the past ten days. A total of 112.51M shares are outstanding, with a floating share count of 74.54M. Insiders hold about 33.82% of the company’s shares, while institutions hold 62.68% stake in the company. Shares short for NAMS as of 1760486400 were 6855986 with a Short Ratio of 6.54, compared to 1757894400 on 8434726. Therefore, it implies a Short% of Shares Outstanding of 6855986 and a Short% of Float of 7.26.
Earnings Estimates
The market rating for NewAmsterdam Pharma Company NV (NAMS) is a result of the insights provided by 12.0 analysts actively involved in the assessment.The consensus estimate for the next quarter is -$0.38, with high estimates of -$0.26 and low estimates of -$0.49.
Analysts are recommending an EPS of between -$0.94 and -$1.45 for the fiscal current year, implying an average EPS of -$1.19. EPS for the following year is -$1.58, with 10.0 analysts recommending between -$1.12 and -$2.06.
Revenue Estimates
A total of 14 analysts have provided revenue estimates for NAMS’s current fiscal year. The highest revenue estimate was $46.11M, while the lowest revenue estimate was $18.97M, resulting in an average revenue estimate of $27.34M. In the same quarter a year ago, actual revenue was $43.39M
